Pages Menu
TwitterRssFacebook
Categories Menu

Posted by on Jun 14, 2013 in Medical Journals |

UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States.

Head for The Masto Townhall forum to debate this paper.
This article may be copyrighted. Notice to copyright holders.
You can view the full article at the publisher here
There is a fee associated with downloading this article.
Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):247-53.

UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States.

Tuchinda C, Kerr HA, Taylor CR, Jacobe H, Bergamo BM, Elmets C, Rivard J, Lim HW.

Abstract

BACKGROUND:

The efficacy and safety of UVA1 (340-400 nm) phototherapy were established by studies from European countries.

PURPOSE:

Evaluate experience with UVA1 phototherapy for patients with cutaneous diseases in the United States.

METHODS:

A retrospective analysis of 92 cases of UVA1-treated cutaneous conditions from four medical centers in the United States was performed.

RESULTS:

Two-third of the patients showed a fair to good response (26-100% improvement) and one-third of the patients showed a poor response (0-25% improvement). Diseases with a moderate to good response (51-100% improvement) included scleredema adultorum, hand or foot dermatitis, atopic dermatitis, morphea (medium or medium- to high-dose UVA1), systemic sclerosis, and urticaria pigmentosa. Besides tanning, other adverse effects were found in 15% of patients, which include pruritus, erythema, tenderness, and burning sensation. Patients with skin types I-III responded better that those with a darker skin type.

CONCLUSION:

UVA1 phototherapy is a useful and well-tolerated treatment option for a variety of skin conditions.

PMID: 16948826 [PubMed – indexed for MEDLINE]